Skip to content

This study evaluates the effectiveness and safety of a product in helping men with premature ejaculation last longer during intercourse.

A Open label Clinical end point study to evaluate the Efficacy and Safety of NATURAL DELAY SPRAY in Male Patients With Premature Ejaculation - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082740
Enrollment
25
Registered
2025-03-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N531- Ejaculatory dysfunction

Interventions

None listed

Sponsors

Pontika Aerotech Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Informed consent for subjects and partners 2.Men 20-60 years of age 3.Stable monogamous relation at least for 6 months 4.Premature Ejaculation Diagnosis Tool (PEDT) score of less than 9. 5.At least 6 months of premature ejaculation History 6.IELT (Intravaginal ejaculation latency time) of 2 min and more than 75% of evaluable events during 4 week screening period

Exclusion criteria

Exclusion criteria: 1.History of medical or psychiatric illness 2.Erectile dysfunction (21 International Index of Erectile Function-Erectile Function (IIEF-EF) domain score) or other forms of sexual dysfunction 3.Partner sexual dysfunction 4.Known hypersensitivity to the ingredients of the test product. 5.Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact the study outcome. 6.History of drug or alcohol abuse during the last 3 months.

Design outcomes

Primary

MeasureTime frame
1. Intravaginal ejaculation latency time (IELT) 2. Sexual satisfaction will be assessed using a Likert scale. 3. PEDT and AIPE score before and after the treatment of 4 weeks. Timepoint: Baseline and 4 weeks

Secondary

MeasureTime frame
Clinical safety assessments, including weight, blood pressure, pulse and adverse eventsTimepoint: Baseline and 4 weeks

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

Grace Trinity Hospital

srkguruvarshan@gmail.com9677786774

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026